AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16898430 — intervention group
Group type: EXPERIMENTAL
Intervention: OASIS Moisturizing Mouthwash
Number of subjects: 49
Study 16898430 — intervention group
Group type: COMPARATOR
Intervention: Experimental mouthwash formulation
Number of subjects: 49
Study 15255163 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan and cisplatin (IP)
Number of subjects: 0
Study 15255163 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan, cisplatin, and etoposide (IPE) administered every 4 weeks (arm B)
Number of subjects: 0
Study 10716459 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 635
Study 10716459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 635
Study 8959290 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular abnormality (VA group)
Number of subjects: 56
Study 8959290 — intervention group
Group type: COMPARATOR
Intervention: Normal CT findings (NCT group)
Number of subjects: 56
Study 1382003 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride
Number of subjects: 8
Study 1382003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1382003 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide
Number of subjects: 8
Study 1382003 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide
Number of subjects: 8
Study 3158320 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel + ethinylestradiol (150 micrograms/30 micrograms; Marvelon)
Number of subjects: 78
Study 3158320 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel + ethinylestradiol (150 micrograms/30 micrograms)
Number of subjects: 78
Study 3158320 — intervention group
Group type: COMPARATOR
Intervention: Triphasic preparation containing levonorgestrel + ethinylestradiol
Number of subjects: 78
Study 31859087 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen-based supplement (1000 kcal)
Number of subjects: 31
Study 31859087 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric placebo
Number of subjects: 31
Study 29764693 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quintile of dietary vitamin B6 intake (men)
Number of subjects: 134480
Study 29764693 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quintile of dietary vitamin B6 intake (women)
Number of subjects: 134480
Study 29764693 — intervention group
Group type: COMPARATOR
Intervention: Lowest quintile of dietary vitamin B6 intake (women)
Number of subjects: 134480
Study 28106331 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose antivenom (20 vials)
Number of subjects: 141
Study 28106331 — intervention group
Group type: COMPARATOR
Intervention: Low-dose antivenom (10 vials) plus 4 U of fresh frozen plasma (FFP)
Number of subjects: 141
Study 25929712 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated extraction of mandibular teeth (second premolars or first molars)
Number of subjects: 25
Study 25929712 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard therapies)
Number of subjects: 25
Study 23475128 — intervention group
Group type: EXPERIMENTAL
Intervention: 4,000 IU vitamin D (n = 23)
Number of subjects: 45
Study 23475128 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 22)
Number of subjects: 45
Study 21216833 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg rosuvastatin
Number of subjects: 1464
Study 21216833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1464
Study 18645050 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg slow-release, once daily)
Number of subjects: 37
Study 18645050 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated group)
Number of subjects: 37
Study 17074656 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC50 (fluorouracil 500 mg/m(2), epirubicin 50 mg/m(2), cyclophosphamide 500 mg/m(2), 6 cycles every 21 days)
Number of subjects: 328
Study 17074656 — intervention group
Group type: COMPARATOR
Intervention: Control (no systemic treatment)
Number of subjects: 328
Study 17074656 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC50
Number of subjects: 328
Study 17074656 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 328
Study 14570789 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway Management Device (AMD)
Number of subjects: 100
Study 14570789 — intervention group
Group type: COMPARATOR
Intervention: classic Laryngeal Mask Airway (cLMA)
Number of subjects: 100
Study 10993030 — intervention group
Group type: COMPARATOR
Intervention: 17beta-estradiol 1 mg
Number of subjects: 145
Study 10993030 — intervention group
Group type: COMPARATOR
Intervention: 17beta-estradiol 0.5 mg
Number of subjects: 145
Study 10993030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 8822775 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for primary health care workers (PHCWs)
Number of subjects: 0
Study 1580773 — intervention group
Group type: EXPERIMENTAL
Intervention: Flex Foot
Number of subjects: 17
Study 1580773 — intervention group
Group type: EXPERIMENTAL
Intervention: Seattle Foot
Number of subjects: 17
Study 1580773 — intervention group
Group type: EXPERIMENTAL
Intervention: Both prostheses
Number of subjects: 17
Study 1580773 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 17
Study 3909321 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous aztreonam (1-2 g every 8 hr)
Number of subjects: 49
Study 3909321 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tobramycin (3-5 mg/kg per day)
Number of subjects: 49
Study 30609986 — intervention group
Group type: EXPERIMENTAL
Intervention: Game‐Motivated ePRO
Number of subjects: 197
Study 30609986 — intervention group
Group type: EXPERIMENTAL
Intervention: ePRO
Number of subjects: 197
Study 30609986 — intervention group
Group type: COMPARATOR
Intervention: Paper PRO
Number of subjects: 197
Study 30609986 — intervention group
Group type: EXPERIMENTAL
Intervention: Average diary completion time
Number of subjects: 197
Study 30609986 — intervention group
Group type: EXPERIMENTAL
Intervention: System Usability Scale score
Number of subjects: 197
Study 30379210 — intervention group
Group type: COMPARATOR
Intervention: C1 (1 pressing)
Number of subjects: 90
Study 30379210 — intervention group
Group type: EXPERIMENTAL
Intervention: CM3 (3 pressings + mechanical cycling)
Number of subjects: 90
Study 30379210 — intervention group
Group type: EXPERIMENTAL
Intervention: CM2 (2 pressings + mechanical cycling)
Number of subjects: 90
Study 30379210 — intervention group
Group type: EXPERIMENTAL
Intervention: C3 (3 pressings)
Number of subjects: 90
Study 30379210 — intervention group
Group type: EXPERIMENTAL
Intervention: CM1 (1 pressing + mechanical cycling)
Number of subjects: 90
Study 30379210 — intervention group
Group type: EXPERIMENTAL
Intervention: C2 (2 pressings)
Number of subjects: 90
Study 30379210 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study 26922019 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung protective ventilation (VT of 6 mL/kg + RMs + PEEP: 5 cmH(2)O (PBW) and RR of 12‐18 /min)
Number of subjects: 60
Study 26922019 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung protective ventilation
Number of subjects: 60
Study 26922019 — intervention group
Group type: COMPARATOR
Intervention: Control group (VT of 10 mL/kg (PBW) and RR of 10‐12 /min)
Number of subjects: 60
Study 24346821 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 1000 mg
Number of subjects: 6
Study 24346821 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) 400 mg
Number of subjects: 6
Study 24346821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 22433024 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interview
Number of subjects: 0
Study 22433024 — intervention group
Group type: COMPARATOR
Intervention: Reminder telephone call
Number of subjects: 0
Study 20642474 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber dam
Number of subjects: 232
Study 20642474 — intervention group
Group type: COMPARATOR
Intervention: Cotton rolls
Number of subjects: 232
Study 17923633 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CE) for symptomatic patients
Number of subjects: 3283
Study 17923633 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CE) for asymptomatic patients
Number of subjects: 3283
Study 14975052 — intervention group
Group type: EXPERIMENTAL
Intervention: T‐piece mode (4 l/min oxygen via a T‐piece for 2 hours)
Number of subjects: 60
Study 14975052 — intervention group
Group type: COMPARATOR
Intervention: Pressure support mode (FiO2 </= 0.4, PS </= 10 cmH2O, and positive end expiratory pressure </= 5 cmH2O for 2 hours)
Number of subjects: 60
Study 14975052 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure mode (FiO2 </= 0.4 and CPAP 5 </= cmH2O for 2 hours)
Number of subjects: 60
Study 11353931 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis with tPA
Number of subjects: 30
Study 11353931 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis with SK
Number of subjects: 30
Study 11353931 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 30
Study 11353931 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 9398955 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 20
Study 9398955 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 20
Study 8214998 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-based heparin nomogram (starting dose, 80 units/kg body weight bolus, 18 units/kg per hour infusion)
Number of subjects: 115
Study 3812340 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet A (high-protein and low-fat diet)
Number of subjects: 12
Study 3812340 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet B (low-protein and high-fat diet)
Number of subjects: 12
Study 31190459 — intervention group
Group type: EXPERIMENTAL
Intervention: Teach-back heart failure self-management intervention plus usual care
Number of subjects: 140
Study 31190459 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 140
Study 30142603 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 accelerated high-frequency (HF)-rTMS sessions at the right dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 22
Study 30142603 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 22
Study 30142603 — intervention group
Group type: COMPARATOR
Intervention: Control group (abstainers)
Number of subjects: 22
Study 30142603 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline GMV
Number of subjects: 22
Study 26818881 — intervention group
Group type: COMPARATOR
Intervention: sham
Number of subjects: 50
Study 26818881 — intervention group
Group type: EXPERIMENTAL
Intervention: right anodal (a-TDCS)
Number of subjects: 50
Study 26818881 — intervention group
Group type: EXPERIMENTAL
Intervention: left cathodal (c-TDCS)
Number of subjects: 50
Study 26818881 — intervention group
Group type: EXPERIMENTAL
Intervention: double source (ds)-TDCS
Number of subjects: 50
Study 26818881 — intervention group
Group type: EXPERIMENTAL
Intervention: classical bilateral stimulation (bi-TDCS)
Number of subjects: 50
Study 24210549 — intervention group
Group type: EXPERIMENTAL
Intervention: Apparent treatment-resistant hypertension
Number of subjects: 10001
Study 22440192 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg and amlodipine besilate 5 mg (CC/AML 8/5 mg)
Number of subjects: 444
Study 22440192 — intervention group
Group type: COMPARATOR
Intervention: Candesartan cilexetil 8 mg (CC 8 mg)
Number of subjects: 444
Study 22440192 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine besilate 5 mg (AML 5 mg)
Number of subjects: 444
Study 22440192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 444
Study 20632489 — intervention group
Group type: COMPARATOR
Intervention: Routine methods and topical oxygen therapy (Group B)
Number of subjects: 85
Study 20632489 — intervention group
Group type: COMPARATOR
Intervention: Routine methods and bFGF therapy (Group C)
Number of subjects: 85
Study 20632489 — intervention group
Group type: COMPARATOR
Intervention: Routine methods and bFGF/topical oxygen therapy (Group D)
Number of subjects: 85
Study 20632489 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine treatment (Group A)
Number of subjects: 85
Study 17717526 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin 10 mg once daily (q.d.)
Number of subjects: 372
Study 17717526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study 16297757 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.1 mg/kg)
Number of subjects: 30
Study 16297757 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol (0.02 mg/kg)
Number of subjects: 30
Study 16297757 — intervention group
Group type: COMPARATOR
Intervention: Control (no premedication)
Number of subjects: 30
Study 11905429 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous oxytocin (10 units)
Number of subjects: 991
Study 11905429 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular syntometrine (1 ml)
Number of subjects: 991
Study 10707131 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 ml of Mydricaine No. 1
Number of subjects: 49
Study 10707131 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Mydricaine No. 1)
Number of subjects: 49
Study 8944370 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine 500 mg thrice daily for 7 days
Number of subjects: 15
Study 8944370 — intervention group
Group type: COMPARATOR
Intervention: Olsalazine 500 mg twice daily for 7 days
Number of subjects: 15
Study 2036478 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus intensity of 70 dB SL
Number of subjects: 6
Study 2036478 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus intensity of 70 dB
Number of subjects: 6
Study 7082112 — intervention group
Group type: EXPERIMENTAL
Intervention: Two weeks of hospitalization
Number of subjects: 138
Study 7082112 — intervention group
Group type: COMPARATOR
Intervention: Three weeks of hospitalization
Number of subjects: 138
Study 7082112 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (two weeks and three weeks of hospitalization)
Number of subjects: 138
Study 31961224 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (2.5 mg) - three intravitreal injections at monthly intervals
Number of subjects: 30
Study 31961224 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone (8 mg) - single injection followed by two sham interventions at monthly intervals
Number of subjects: 30
Study 31524552 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdecision intervention for staff members including systematic listening and offering involvement
Number of subjects: 685
Study 31524552 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdecision intervention
Number of subjects: 685
Study 28934604 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of Lp-PLA2 mass
Number of subjects: 3401
Study 28934604 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of Lp-PLA2 mass with higher LDL-C
Number of subjects: 3401
Study 24482284 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA
Number of subjects: 170
Study 24482284 — intervention group
Group type: COMPARATOR
Intervention: Control (Conventional ventilation)
Number of subjects: 170
Study 23986081 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 60
Study 23986081 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 22397239 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (N = 23)
Number of subjects: 71
Study 22397239 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (N = 22)
Number of subjects: 71
Study 22397239 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ramipril and valsartan (N = 26)
Number of subjects: 71
Study 22397239 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (ramipril + valsartan)
Number of subjects: 71
Study 22397239 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (ramipril or valsartan)
Number of subjects: 71
Study 18583434 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA)
Number of subjects: 52
Study 18583434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 17509426 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (twice per day dosing regimen: one dose before and three doses after contrast media exposure)
Number of subjects: 40
Study 17509426 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice per day dosing regimen: one dose before and three doses after contrast media exposure)
Number of subjects: 40
Study 17509426 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 40
Study 17509426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 14715839 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg melatonin daily for 4 weeks
Number of subjects: 14
Study 14715839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 14715839 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg melatonin daily for 4 weeks (second study)
Number of subjects: 14
Study 14715839 — intervention group
Group type: COMPARATOR
Intervention: Melatonin in the first study and placebo in the second
Number of subjects: 14
Study 11180024 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg once daily
Number of subjects: 12
Study 11180024 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg once daily
Number of subjects: 12
Study 9368234 — intervention group
Group type: EXPERIMENTAL
Intervention: intensive oral + i.v. magnesium supplementation
Number of subjects: 11
Study 1609935 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus plus infusion (4 ml incremental bolus with 15 minute lockout, plus a 4 ml per hour infusion of 0.125% bupivacaine plus fentanyl 3 mcg per ml)
Number of subjects: 52
Study 1609935 — intervention group
Group type: COMPARATOR
Intervention: Bolus only (4 ml incremental bolus with 15 minute lockout of 0.125% bupivacaine plus fentanyl 3 mcg per ml)
Number of subjects: 52
Study 4012373 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise groups
Number of subjects: 50
Study 4012373 — intervention group
Group type: COMPARATOR
Intervention: Nonexercising women
Number of subjects: 50
Study 3594511 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopamide monotherapy
Number of subjects: 49
Study 3594511 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol monotherapy
Number of subjects: 49
Study 3594511 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined pindolol-clopamide therapy
Number of subjects: 49
Study 27139595 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy plus gratitude writing
Number of subjects: 293
Study 27139595 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy plus expressive writing
Number of subjects: 293
Study 27139595 — intervention group
Group type: COMPARATOR
Intervention: Psychotherapy only (control)
Number of subjects: 293
Study 28579062 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-widefield fluorescein angiography
Number of subjects: 40
Study 28579062 — intervention group
Group type: EXPERIMENTAL
Intervention: NPA and ISI measurements
Number of subjects: 40
Study 28579062 — intervention group
Group type: EXPERIMENTAL
Intervention: NPA and ISI in midperiphery
Number of subjects: 40
Study 28579062 — intervention group
Group type: EXPERIMENTAL
Intervention: Global NPA and ISI
Number of subjects: 40
Study 26043562 — intervention group
Group type: EXPERIMENTAL
Intervention: Wuling Capsule (0.33 g/capsule, 3 times per day) + Pinaverium Bromide (50 mg/tablet, 3 times per day)
Number of subjects: 64
Study 26043562 — intervention group
Group type: COMPARATOR
Intervention: Pinaverium Bromide (50 mg/tablet, 3 times per day)
Number of subjects: 64
Study 26043562 — intervention group
Group type: EXPERIMENTAL
Intervention: Wuling Capsule + Pinaverium Bromide
Number of subjects: 64
Study 26043562 — intervention group
Group type: COMPARATOR
Intervention: Pinaverium Bromide
Number of subjects: 64
Study 23829154 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine gum (100 mg)
Number of subjects: 15
Study 23829154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 20070920 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive activities designed around Piagetian concrete operational schemata
Number of subjects: 275
Study 20070920 — intervention group
Group type: EXPERIMENTAL
Intervention: Mathematics lessons in both Year 1 and Year 2 based on theories from Piaget and Vygotsky
Number of subjects: 275
Study 18249334 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 52
Study 18249334 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 52
Study 16341026 — intervention group
Group type: EXPERIMENTAL
Intervention: Hood nebulization
Number of subjects: 10
Study 16341026 — intervention group
Group type: COMPARATOR
Intervention: Mask nebulization
Number of subjects: 10
Study 14623808 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (0.125 mg/min)
Number of subjects: 7
Study 14623808 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (0.5 mg/min)
Number of subjects: 7
Study 14623808 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (loading dose, 0.142 mg/kg per min for 5 minutes followed by 0.004 mg/kg per min)
Number of subjects: 7
Study 14623808 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 7
Study 10632647 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg o.d. for the first 6 days (PAAz group; n=55)
Number of subjects: 110
Study 10632647 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin 500 mg b.d. for the first 7 days (PAC group; n=55)
Number of subjects: 110
Study 9197294 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion
Number of subjects: 15
Study 9197294 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 15
Study 1606114 — intervention group
Group type: EXPERIMENTAL
Intervention: Two catheters tied together introduced transcervically into the same amniotic fluid pocket
Number of subjects: 20